Indian Journal of Urology Users online:7494  
IJU
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size

  Article Access Statistics

Year : 2022 | Volume:  38 | Issue Number:  3 | Page:  238-239

UROSCAN

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
Kumar Naveen

Number of times this article was viewed 766
Number of times this article has been printed  from the site 22
Number of times this article was emailed to others 0
Remarks given by readers [ Read ] 0

 

  Search 
  The Journal 
  The Association 
  Site Statistics 
  Addresses 
  e-Alerts 
  Online Submission 
 Back To Article

Submit Articles

Alerts

Join us